# TELA Bio, Inc. (TELA) — management_change/board [announced]
Source: sec.gov · situation sit_3ba52a41573eb819ef8c · public 3009121850025980308 · retrieved 2026-08-20T13:19:52.318Z

## Overview
TELA Bio, Inc. is a surgical and medical instruments company engaged in the development and commercialization of medical devices.

TELA Bio's Board determined that Chief Executive Officer Antony Koblish would no longer serve in that role as of August 3, 2026. On August 7, 2026, the Company and Mr. Koblish entered into a Separation Agreement and General Release. Under the agreement, Mr. Koblish receives all accrued and unpaid base salary through the separation date, 12 months of base salary paid ratably over 12 months beginning on the first payroll date following August 7, 2026, and COBRA premium coverage for 12 months if he timely elects continuation by September 1, 2026. All of Mr. Koblish's equity awards under the Company's Amended and Restated 2019 Equity Incentive Plan and any other equity plan immediately accelerate and become fully vested and exercisable as of the effective date. His option exercise period is extended until the earlier of December 31, 2027 or the applicable expiration date, subject to earlier termination upon a change in control. Performance stock units remain outstanding and eligible to vest upon achievement of annual revenue and gross margin goals through December 31, 2026, or vest at target if a change in control occurs by that date.

## Terms
- Counterparty: Antony Koblish

## Key dates
- Announced 2026-08-13 · Expiry 2027-12-31

## Timeline
- 2026-08-13 · 8-K/A (0001104659-26-095892): 8-K/A - TELA Bio, Inc. — *TELA Bio, Inc. is a surgical and medical instruments company engaged in the development and commercialization of medical devices.* TELA Bio's Board determined that Chief Executive Officer Antony Koblish would no longer serve in that role as of August 3, 2026. On August 7, 2026, the Company and Mr. Koblish entered into a Separation Agreement and General Release. Under the agreement, Mr. Koblish receives all accrued and unpaid base salary through the separation date, 12 months of base salary paid ratably over 12 months beginning on the first payroll date following August 7, 2026, and COBRA premium coverage for 12 months if he timely elects continuation by September 1, 2026. All of Mr. Koblish's equity awards under the Company's Amended and Restated 2019 Equity Incentive Plan and any other equity plan immediately accelerate and become fully vested and exercisable as of the effective date. His option exercise period is extended until the earlier of December 31, 2027 or the applicable expiration date, subject to earlier termination upon a change in control. Performance stock units remain outstanding and eligible to vest upon achievement of annual revenue and gross margin goals through December 31, 2026, or vest at target if a change in control occurs by that date.
  https://www.sec.gov/Archives/edgar/data/1561921/0001104659-26-095892.txt

## Citations
- 0001104659-26-095892 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926095892